P11473 |
VDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P11473 |
VDR_HUMAN |
Hair/hair growth developmental defect [ICD-11: LC30] |
P11473 |
VDR_HUMAN |
Hyper-parathyroidism [ICD-11: 5A51] |
P11473 |
VDR_HUMAN |
Hypo-parathyroidism [ICD-11: 5A50] |
P11473 |
VDR_HUMAN |
Mineral deficiency [ICD-11: 5B5K] |
P11473 |
VDR_HUMAN |
Psoriasis [ICD-11: EA90] |
P11473 |
VDR_HUMAN |
Vitamin deficiency [ICD-11: 5B55-5B5F] |
P11473 |
VDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P11473 |
VDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P11473 |
VDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P11473 |
VDR_HUMAN |
Prostate disease [ICD-11: GA91] |
P11473 |
VDR_HUMAN |
Abnormal micturition [ICD-11: MF50] |
P11473 |
VDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P11473 |
VDR_HUMAN |
Postoperative inflammation [ICD-11: 1A00-CA43] |
P11473 |
VDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
Q16637 |
SMN_HUMAN |
Muscular atrophy [ICD-11: 8B61] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Acute myeloid leukaemia [ICD-11: 2A60] |
P10275 |
ANDR_HUMAN |
Alcoholic liver disease [ICD-11: DB94] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Cardiovascular disease [ICD-11: BA00-BE2Z] |
P10275 |
ANDR_HUMAN |
Chronic obstructive pulmonary disease [ICD-11: CA22] |
P10275 |
ANDR_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P10275 |
ANDR_HUMAN |
Hypo-osmolality/hyponatraemia [ICD-11: 5C72] |
P10275 |
ANDR_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P10275 |
ANDR_HUMAN |
Mammary tumour [ICD-11: 2C60-2C6Z] |
P10275 |
ANDR_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Testicular dysfunction [ICD-11: 5A81] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Alopecia [ICD-11: ED70] |
P10275 |
ANDR_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
P10275 |
ANDR_HUMAN |
Thrombosis [ICD-11: DB61-GB90] |
P10275 |
ANDR_HUMAN |
Contraceptive management [ICD-11: QA21] |
P10275 |
ANDR_HUMAN |
Heart failure [ICD-11: BD10-BD1Z] |
P10275 |
ANDR_HUMAN |
Muscle disorder [ICD-11: FB32-FB3Z] |
P10275 |
ANDR_HUMAN |
Muscular dystrophy [ICD-11: 8C70] |
P10275 |
ANDR_HUMAN |
Cystic fibrosis [ICD-11: CA25] |
P10275 |
ANDR_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P10275 |
ANDR_HUMAN |
Cachexia [ICD-11: MG20] |
P10275 |
ANDR_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P10275 |
ANDR_HUMAN |
Bladder cancer [ICD-11: 2C94] |
P10275 |
ANDR_HUMAN |
Oesophagitis [ICD-11: DA24] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10275 |
ANDR_HUMAN |
Prostate hyperplasia [ICD-11: GA90] |
P10275 |
ANDR_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P10275 |
ANDR_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P10275 |
ANDR_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P10275 |
ANDR_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
Q16236 |
NF2L2_HUMAN |
Ataxic disorder [ICD-11: 8A03] |
Q16236 |
NF2L2_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q16236 |
NF2L2_HUMAN |
Glaucoma [ICD-11: 9C61] |
Q16236 |
NF2L2_HUMAN |
Lung cancer [ICD-11: 2C25] |
Q16236 |
NF2L2_HUMAN |
Macular degeneration [ICD-11: 9B75] |
Q16236 |
NF2L2_HUMAN |
Melanoma [ICD-11: 2C30] |
Q16236 |
NF2L2_HUMAN |
Mental/behavioural/neurodevelopmental disorder [ICD-11: 6E20-6E8Z] |
Q16236 |
NF2L2_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
Q16236 |
NF2L2_HUMAN |
Subarachnoid haemorrhage [ICD-11: 8B01] |
Q16236 |
NF2L2_HUMAN |
Urinary system clinical sympton [ICD-11: MF8Y] |
Q16236 |
NF2L2_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q16236 |
NF2L2_HUMAN |
Alpha-1-antitrypsin deficiency [ICD-11: 5C5A] |
Q16236 |
NF2L2_HUMAN |
Motor neuron disease [ICD-11: 8B60] |
Q16236 |
NF2L2_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P03372 |
ESR1_HUMAN |
Acne vulgaris [ICD-11: ED80] |
P03372 |
ESR1_HUMAN |
Acquired prion disease [ICD-11: 8E01] |
P03372 |
ESR1_HUMAN |
Adrenal cancer [ICD-11: 2D11] |
P03372 |
ESR1_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
P03372 |
ESR1_HUMAN |
Contraceptive management [ICD-11: QA21] |
P03372 |
ESR1_HUMAN |
Dyspareunia [ICD-11: GA12] |
P03372 |
ESR1_HUMAN |
Female infertility [ICD-11: GA31] |
P03372 |
ESR1_HUMAN |
Low bone mass disorder [ICD-11: FB83] |
P03372 |
ESR1_HUMAN |
Male infertility [ICD-11: GB04] |
P03372 |
ESR1_HUMAN |
Menopausal disorder [ICD-11: GA30] |
P03372 |
ESR1_HUMAN |
Menstrual cycle bleeding disorder [ICD-11: GA20] |
P03372 |
ESR1_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P03372 |
ESR1_HUMAN |
Pituitary gland disorder [ICD-11: 5A60-5A61] |
P03372 |
ESR1_HUMAN |
Skeletal anomaly [ICD-11: LD24] |
P03372 |
ESR1_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P03372 |
ESR1_HUMAN |
Vaginitis [ICD-11: GA02] |
P03372 |
ESR1_HUMAN |
Virus infection [ICD-11: 1A24-1D9Z] |
P03372 |
ESR1_HUMAN |
Endometriosis [ICD-11: GA10] |
P03372 |
ESR1_HUMAN |
Female genital tract noninflammatory disorder [ICD-11: GA1Y] |
P03372 |
ESR1_HUMAN |
Female pelvic pain [ICD-11: GA34] |
P03372 |
ESR1_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P03372 |
ESR1_HUMAN |
Breast in situ carcinoma [ICD-11: 2E65] |
P03372 |
ESR1_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P03372 |
ESR1_HUMAN |
Prostate cancer [ICD-11: 2C82] |
P03372 |
ESR1_HUMAN |
Brain cancer [ICD-11: 2A00] |
P03372 |
ESR1_HUMAN |
Metastatic tumour [ICD-11: 2D50-2E2Z] |
P03372 |
ESR1_HUMAN |
Irregularities [ICD-11: N.A.] |
P03372 |
ESR1_HUMAN |
Trematode disease [ICD-11: 1F8Y] |
P03372 |
ESR1_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P03372 |
ESR1_HUMAN |
Eye disorder [ICD-11: 9A01-9A0Z] |
P03372 |
ESR1_HUMAN |
Dissociative neurological symptom disorder [ICD-11: 6B60] |
P03372 |
ESR1_HUMAN |
Thrombocytopenia [ICD-11: 3B64] |
P03372 |
ESR1_HUMAN |
Atrophy [ICD-11: 9A2Y-9C40] |
P03372 |
ESR1_HUMAN |
Joint pain [ICD-11: ME82] |
P03372 |
ESR1_HUMAN |
Sexual dysfunction [ICD-11: HA00-HA01] |
P03372 |
ESR1_HUMAN |
Leukaemia [ICD-11: 2A60-2B33] |
P25779 |
CYSP_TRYCR |
Parasitic worm infestation [ICD-11: 1F90] |
P25779 |
CYSP_TRYCR |
Malaria [ICD-11: 1F40-1F45] |
P37231 |
PPARG_HUMAN |
Pulmonary hypertension [ICD-11: BB01] |
P37231 |
PPARG_HUMAN |
Sjogren syndrome [ICD-11: 4A43] |
P37231 |
PPARG_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 |
PPARG_HUMAN |
Acute diabete complication [ICD-11: 5A2Y] |
P37231 |
PPARG_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
P37231 |
PPARG_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
P37231 |
PPARG_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
P37231 |
PPARG_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
P37231 |
PPARG_HUMAN |
Glaucoma [ICD-11: 9C61] |
P37231 |
PPARG_HUMAN |
Inborn lipid metabolism error [ICD-11: 5C52] |
P37231 |
PPARG_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P37231 |
PPARG_HUMAN |
Gout [ICD-11: FA25] |
P37231 |
PPARG_HUMAN |
Indeterminate colitis [ICD-11: DD72] |
P37231 |
PPARG_HUMAN |
Multiple sclerosis [ICD-11: 8A40] |
P37231 |
PPARG_HUMAN |
Nicotine use disorder [ICD-11: 6C4A] |
P37231 |
PPARG_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
P37231 |
PPARG_HUMAN |
Opioid use disorder [ICD-11: 6C43] |
P37231 |
PPARG_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
P37231 |
PPARG_HUMAN |
Idiopathic interstitial pneumonitis [ICD-11: CB03] |
P37231 |
PPARG_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 |
PPARD_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q03181 |
PPARD_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |
Q03181 |
PPARD_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q03181 |
PPARD_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q03181 |
PPARD_HUMAN |
Obesity [ICD-11: 5B80-5B81] |
Q03181 |
PPARD_HUMAN |
Alzheimer disease [ICD-11: 8A20] |
Q03181 |
PPARD_HUMAN |
Dyslipidemia [ICD-11: 5C80-5C81] |
Q03181 |
PPARD_HUMAN |
Metabolic disorder [ICD-11: 5C50-5D2Z] |
Q03181 |
PPARD_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q03181 |
PPARD_HUMAN |
Central nervous system disease [ICD-11: 8A04-8D87] |
P19793 |
RXRA_HUMAN |
Kaposi sarcoma [ICD-11: 2B57] |
P19793 |
RXRA_HUMAN |
Mycosis fungoides [ICD-11: 2B01] |
P10145 |
IL8_HUMAN |
Pain [ICD-11: MG30-MG3Z] |
P10145 |
IL8_HUMAN |
COVID-19 [ICD-11: 1D6Y] |
P10145 |
IL8_HUMAN |
Melanoma [ICD-11: 2C30] |
P10145 |
IL8_HUMAN |
Solid tumour/cancer [ICD-11: 2A00-2F9Z] |
P10145 |
IL8_HUMAN |
Diabetes mellitus [ICD-11: 5A10] |
Q96RI1 |
NR1H4_HUMAN |
Autoimmune liver disease [ICD-11: DB96] |
Q96RI1 |
NR1H4_HUMAN |
Cholelithiasis [ICD-11: DC11] |
Q96RI1 |
NR1H4_HUMAN |
Insomnia [ICD-11: 7A00-7A0Z] |
Q96RI1 |
NR1H4_HUMAN |
Osteoarthritis [ICD-11: FA00-FA05] |
Q96RI1 |
NR1H4_HUMAN |
Breast cancer [ICD-11: 2C60-2C6Y] |
Q96RI1 |
NR1H4_HUMAN |
Non-alcoholic fatty liver disease [ICD-11: DB92] |
Q96RI1 |
NR1H4_HUMAN |
Chronic kidney disease [ICD-11: GB61] |
Q96RI1 |
NR1H4_HUMAN |
Skeletal anomaly [ICD-11: LD24] |
Q96RI1 |
NR1H4_HUMAN |
Hepatic fibrosis/cirrhosis [ICD-11: DB93] |
Q96RI1 |
NR1H4_HUMAN |
Hyper-lipoproteinaemia [ICD-11: 5C80] |
Q96RI1 |
NR1H4_HUMAN |
Type 2 diabetes mellitus [ICD-11: 5A11] |